| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917823 | Radiotherapy and Oncology | 2016 | 11 Pages |
Abstract
In addition to SPCs, dose to MHM should be monitored and constrained, especially in older patients (>62-years), when feasible.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
